ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed a cooperation memorandum of understanding (MoU) with Takeda (TYO: 4502). This partnership aims to jointly explore opportunities in early development, new technology application, and innovative company empowerment, with a focus on oncology, neuroscience, digestive, and inflammatory diseases.
Scope of Collaboration
The collaboration will leverage Takeda’s extensive global experience in disease pathology research, drug target screening, translational medicine, preclinical research and development, and other critical areas. By combining forces, ATLATL and Takeda aim to accelerate advancements in the identified therapeutic areas, potentially leading to breakthroughs in patient care and treatment options.
ATLATL’s Comprehensive R&D Services
ATLATL operates R&D centers in Beijing, Shanghai, Shenzhen, Singapore, and Hong Kong, offering customers a wide range of comprehensive research and development services. These services span various stages of drug development, including drug activity testing, animal disease model construction, and efficacy evaluation. ATLATL’s expertise covers macromolecules, small molecules, nucleic acid drugs, gene and cell therapy, drug delivery, and cutting-edge fields such as multi-omics analysis, gene editing, organoids, and organ-on-a-chip technology.-Fineline Info & Tech
Leave a Reply